Earlier studies have shown both p53-dependent and -independent tumor-suppressive functions of B56c-specific protein phosphatase 2A (B56c-PP2A). In the absence of p53, B56c-PP2A can inhibit cell proliferation and cell transformation by an unknown mechanism. In the presence of p53, on DNA damage, a complex including B56c-PP2A and p53 is formed, which leads to Thr55 dephosphorylation of p53, induction of the p53 transcriptional target p21 and inhibition of cell proliferation. In spite of its significance in inhibition of cell proliferation, no B56c mutations have been linked to human cancer to date. In this study, we first differentiate between the p53-dependent and -independent functions of B56c-PP2A by identifying a domain of the B56c protein required for interaction with p53. Within this region, we identify a B56c mutation, F395C, in lung cancer that disrupts the B56c-p53 interaction. More importantly, we show that F395C is unable to promote p53 Thr55 dephosphorylation, transcriptional activation of p21 and the p53-dependent tumor-suppressive function of PP2A. This finding provides a mechanistic basis for the p53-dependent and -independent functions of B56c-PP2A and establishes a critical link between B56c-PP2A p53-dependent tumor-suppressive function and tumorigenesis.
Introduction
Protein phosphatase 2A (PP2A) is a family of serine/ threonine phosphoprotein phosphatases that have been implicated as a potential tumor-suppressor. PP2A consists of a heterotrimeric complex composed of a scaffolding (A) subunit, catalytic (C) subunit and regulatory (B) subunit. The B subunit is postulated to confer substrate specificity to the PP2A holoenzyme (Janssens and Goris, 2001; Schonthal, 2001; Eichorn et al., 2009; Virshup and Shenolikar, 2009 ). The role of PP2A in control of tumor progression is thought to be governed by a small subset of specific B subunits directing PP2A to dephosphorylate and regulate key tumor suppressors or oncogenes (Eichorn et al., 2009; Virshup and Shenolikar, 2009 ). Indeed, several members of the B56 family have been described as having a role in directing PP2A potential tumor-suppressive activity. It has been shown that B56a-PP2A (PPP2R5A) dephosphorylates the c-myc oncogene at Ser62, leading to its inactivation (Arnold and Sears, 2006) ; B56d-PP2A (PPP2R5D) dephosphorylates Cdc25, blocking cellcycle progression (Margolis et al., 2006; Forester et al., 2007) ; and B56g-PP2A (PPP2R5C) was shown to be important in SV40-mediated cell transformation (Chen et al., 2004) . Interestingly, mutational analyses of PP2A genes have yielded data suggesting PP2A Aa and Ab mutations are present in some cancers (Wang et al., 1998; Ruediger et al., 2001a, b; Chen et al., 2005; Esplin et al., 2006) . Importantly, the unifying effect of these mutations is loss of interaction with the B56 subunit family members. Although one mutation in the B56e (PPP2R5E) gene of the B56 family has been reported to associate with increased risk of soft tissue sarcoma (Grochola et al., 2009) , no mutations in B56a, B56d and B56g tumor suppressors have been linked to human cancer to date.
p53 is a very important highly studied tumor-suppressor protein that functions primarily as a transcription factor (Kruse and Gu, 2009; Vousden and Prives 2009) . In response to DNA damage, p53 is highly posttranslationally modified, promoting its activation and nuclear localization, whereby it functions as a transcription factor, turning on genes responsible for apoptosis or cell-cycle arrest, including the CDK inhibitor, p21 (Bode and Dong, 2004) . Our laboratory has previously shown that in response to DNA damage, B56g-PP2A dephosphorylates p53 at Thr55 and promotes its transcriptional activation. In addition, we were able to describe both a p53-dependent and -independent tumor-suppressive function of B56g-PP2A (Li et al., 2007; Shouse et al., 2008) . These results led us to focus our investigations toward identifying the region of B56g required for interaction with p53 in an attempt to better understand its p53dependent and -independent functions.
In this study, we show that a small region of B56g (aa391-402) is critical for interaction with the tumor-suppressor protein p53. Within this region, we identify a cancer-derived mutation, F395C, which disrupts the B56g-p53 interaction. Although this mutation has been found from only one human cancer sample thus far, we were able to further show that F395C lacks the ability to promote p53 Thr55 dephosphorylation and transcriptional activation of the p21 gene. Importantly, we show that F395C is unable to drive the previously described p53-dependent tumorsuppressive functions of PP2A, either by inhibiting cell proliferation or by decreasing anchorage-independent growth of tumor-derived cells, while retaining its p53-independent functions. Taken together, these results provide evidence that PP2A-mediated activation of p53 may have an important role in prevention of tumor progression.
Results

Identification of a domain of B56g required for interaction with p53
The B56g gene product directs PP2A phosphatase activity toward p53, promoting p53 Thr55 dephosphorylation, activation and tumor-suppressive function. We sought to better understand the region of the B56g protein required for interaction with p53. To this end, we compared the amino-acid sequences of two different spliced forms of B56g protein, B56g1 and B56g3, able to interact with p53, and the highly related B56a protein, which is unable to interact with p53 (Li et al., 2007) . We posited that the more variable regions found toward the C-and N-terminus ( Figure 1a ) of B56g were most likely the areas of potential interaction with p53 because of their variation from the sequence of the noninteracting B56a protein and their position in the potential substrate-binding area of the B56g-PP2A holoenzyme complex as described in crystallographic studies (Cho and Xu, 2006; Xu et al., 2006) . To test this, we constructed several B56g deletion mutants as glutathione S-transferase fusion proteins and assayed their ability to interact with the PP2A core and p53 ( Figure 1a ). Deletion of the N-terminal 156 amino acids (DN156) or the C-terminus after amino acid 401 (DC401) disrupted the interaction between B56g and the AC core of PP2A. Interestingly, although the DN156 and DC401 mutants were no longer able to interact with the PP2A core, they were still able to bind to p53 to a level similar to that of wild-type B56g3 and B56g1. Significantly, the DC347 and DC376 mutants lost p53 interaction, suggesting that the deleted region may be required for interaction with p53. To confirm this result, we show that DN156, DC376 and DC401 mutants also disrupted interaction with the PP2A core in vivo ( Figure 1b ). In addition, the DC376 mutant lost interaction with p53 in vivo, whereas DC401 and DN156 mutants still maintained interaction (Figure 1b) .
To exclude the possibility that our result could be explained by a loss of proper conformation because of the deletion, we conducted peptide competition experiments using a peptide consisting of the amino acids of B56g from 376 to 402 (peptide B56g, Figure 1c ). The assay showed that the B56g peptide was clearly able to compete out the p53 interaction. An additional smaller peptide containing amino acids 391-402 (peptide 391) was also able to block the interaction, whereas a peptide containing amino acids 376-388 (peptide 376) was unable to do so. A combination of both smaller peptides showed results similar to those of peptide 391 only. As a control, a peptide consisting of amino acids from the corresponding region of homology from B56a (peptide B56a) was unable to block the p53 interaction, as expected. These data suggest that the amino acids on B56g from 391 to 402 constitute a domain required for interaction with p53.
To provide further evidence, we designed and generated four B56g3 point mutants, Q392G, C398L, the double mutant Q392G/C398L (QC) and the double mutant QQ400/401SS (QQ), in which B56g amino acids were mutated to the corresponding amino acids present on B56a (Figure 1c ). We assayed for the effects of the mutations on interaction with p53 and the PP2A core in vivo ( Figure 1d ). Although the interaction was constant between the PP2A core and each of the B subunit constructs expressed, p53 interaction with the QC mutant was almost undetectable and no interaction was detected with the B56a-negative control. Interestingly, both Q392 and C398 single mutants retained their ability to interact with p53. To confirm these results, we performed p53 IP, followed by immunoblotting with an anti-HA antibody, and showed that the QC mutant and B56a are indeed unable to interact with p53 ( Figure 1d , right). We previously showed an endogenous interaction between PP2A and p53 that can be strongly enhanced by B56g3 overexpression (Li et al., 2007) . Blotting with the PP2A C subunit showed that the enhanced interaction between p53 and PP2A observed in the presence of overexpressed B56g3 was lost in the presence of the QC mutant, suggesting that the QC mutant lost its ability to interact with p53. Overall, these results provide additional evidence of the importance of the region of B56g between amino acids 391 and 402 for p53 interaction.
A cancer-derived B56g3 mutant, F395C, is unable to interact with p53 or promote Thr55 dephosphorylation To continue to investigate the importance of this region in tumor progression, we analyzed annotated complementary DNA sequences within our p53 interaction domain present in public databases that were derived from human cancer cell lines and tumor samples, and identified a mutation of a phenylalanine residue at amino-acid position 395 of B56g3 that was mutated to cysteine present in a lung tumor sample (Neto et al., 2006) . As this mutation was present within our identified p53 interaction domain (Figure 2f ), we tested whether this mutation could disrupt interaction with p53. Although the F395C mutant was able to interact normally with the PP2A A and C subunits, it specifically lost its ability to interact with p53 ( Figure 2a ). The interaction with the QC mutant was shown as a negative control. To provide further evidence for specificity, we tested the ability of F395C to bind to several other PP2A substrates, such as cyclin G2 (Bennin et al., 2002) , ERK (Letourneux et al., 2006) and Shugosin (Riedel et al., 2006) . As shown in Figure 2e , F395C, although defective in p53 binding, retains its ability to bind to cyclin G2, ERK and Shugosin. Together, these results suggest that the F395C mutant is unable to specifically interact with p53 and thus unable to recruit the PP2A core to p53.
To test this directly, we assayed the ability of the F395C mutant to promote p53 Thr55 dephosphorylation and p21 induction. As shown in Figure 2a , overexpression of wild-type B56g3 promoted efficient dephosphorylation of p53 at Thr55, compared with the empty vector control. This dephosphorylation correlated with an induction of the p53 transcriptional target p21, underscoring the functional significance of the dephosphorylation. Overexpression of the F395C mutant, however, was unable to promote p53 Thr55 dephosphorylation or p21 induction, suggesting that this mutant has lost its ability to direct PP2A phosphatase activity toward p53. In addition, the QC mutant was also unable to promote Thr55 dephosphorylation or p21 induction, providing evidence that interaction with p53 is required for the tumor-suppressive function of B56g-PP2A. In addition, as shown in Figure 2b , mutants able to interact with p53, including Q392G, C398L and the QQ double mutant, promoted p53 Thr55 dephosphorylation and induction of p21 Figure 1 Mapping of the B56g domain required for interaction with p53. (a) Left: diagram of amino-acid sequences of B56a, B56g and various B56g deletion constructs aligned on the basis of sequence homology. Shades of gray indicate an increasing percentage of identical amino acids within that region. Right: each of the B56g constructs was expressed in bacteria as glutathione S-transferase (GST) fusion proteins, purified and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (upper). U2OS cell lysates were incubated with the purified GST-fusion proteins indicated, then analyzed by western blot against p53, PP2A A and C, and vinculin (vinc) (lower). (b) U2OS cells were transfected with the HA-tagged B56g constructs listed, lysed and subjected to immunoprecipitation with anti-HA antibody. The precipitated proteins were analyzed by western blot against p53, PP2A A and C, HA and vinculin (vinc). (c) 35 S-p53 was incubated with GST protein (GST), GST-B56g3 protein or GST-B56g3 with peptides corresponding to amino acids 376 to 402 (B56g), 376-388 (376) or 391-402 of B56g3 (391), or amino acids 411-437 of B56a (B56a). Amino-acid sequence of the p53-interaction domain of B56g aligned with the homologous sequence of B56a is shown below. (d) Lysates of U2OS cells transfected with HA-tagged B56g3, Q392G, C398L, Q392G/C398L (QC), Q400S/Q401S (QQ) mutant B56g3 or B56a were either immunoprecipitated with anti-HA antibody, then analyzed by western blot against p53, PP2A A and C, HA and vinculin (vinc) (left) or with anti-p53 antibody, then analyzed by western blot against HA, PP2A C, p53 and vinculin (vinc) (right). protein to levels similar to that of wild-type B56g3. Taken together with the interaction results, we have shown that a cancer-derived mutation of B56g3 may disrupt a physiologically significant function of PP2A in preventing tumor progression through activation of p53.
To investigate the potential of the F395C mutant to block the function of the endogenous B56g protein, we assayed for p53 Thr55 dephosphorylation and p21 induction after DNA damage in the presence of exogenous wild-type B56g3, F395C mutant B56g3 or an empty vector control (Figure 2c ). In the case of controls, efficient Thr55 dephosphorylation and induction of p21 protein occur after DNA damage. In the presence of exogenous wild-type B56g3, Thr55 phosphorylation levels are already lower under mock conditions, and further dephosphorylation is observed after IR, whereas p21 levels are higher in the mock lane and increase further after IR. Importantly, in the presence of the F395C mutant, Thr55 phosphorylation levels do not decrease after DNA damage and induction of the p53 transcriptional target p21 is also blocked. This result questions whether the F395C mutant could potentially function as a dominant-negative mutant when present at a level similar to that of endogenous wild-type protein. To test this possibility, we titrated the amount of overexpressed protein and assayed for the effect on Thr55 phosphorylation after DNA damage ( Figure 2d ). Decreasing the level of F395C expression to a level similar to that of endogenous protein (0.25-0.5 mg) led to some Thr55 dephosphorylation after DNA damage, whereas higher levels of F395C expression completely blocked this function. This finding suggests that F395C may be able to function as a dominantnegative mutant by competing with wild-type B56g for binding to the PP2A core, thereby blocking C subunitsubstrate interactions. To further support this view, we assayed for the ability of either wild-type or F395C mutant B56g3 to interact with the endogenous B56g protein (Supplementary Figure S1) . No interaction was detected between exogenous protein and the endogenous B56g, suggesting that the inhibitory mechanism of F395C overexpression is probably through competitive binding to the AC core of PP2A or due to some unknown factors.
Cancer-derived mutant B56g3 lacks p53-dependent tumor-suppressive functions Although the F395C mutation was found in a tumor sample, we wanted to elucidate whether the mutation could directly contribute to a cancer phenotype. We previously showed that wild-type B56g overexpression decreased anchorage-independent growth and cell proliferation rates using a p53-dependent mechanism (Li et al., 2007) . On the basis of our findings that F395C mutant B56g3 lacks interaction with p53 and ability to promote p53 activation, we first tested whether it could function to block anchorage-independent cell growth in a p53-dependent manner. HCT116 cells with either a p53À/À or p53 þ / þ background were transfected with each of the B56g3 constructs, including F395C, QC, wild type, Q392G, C398L and QQ, or an empty vector control and seeded in soft agar. As shown in Figure 3 , overexpression of each of the B56g3 constructs into HCT116 cells lacking p53 led to a similar decrease in the number of colonies present in the agar, from approximately 280 colonies in the empty vector control to approximately 250 colonies. In the presence of p53, however, only those B56g3 constructs able to interact with p53, namely, wild type, Q392G, C398L and QQ, showed a more dramatic decrease in colony number from approximately 250 colonies in the empty vector control to around 75 colonies. Expression of the F395C mutant led to a decrease in colony number, but only to an extent similar to that observed in the absence of p53 corresponding to around 210 colonies. Statistical analysis of the data is shown in Supplementary Figure S2 . This finding suggests that F395C mutant B56g3 is no longer able to function as a p53-dependent tumor-suppressor protein. Samples from transfected cells were analyzed for p21 induction. A strong correlation was shown between the ability of a B56g3 construct to interact with p53, promote p21 induction, and the ability of that construct to block anchorage-independent growth in a p53-dependent manner.
To provide further evidence that F395C mutant B56g3 lacks p53-dependent tumor-suppressive function, we tested whether expression of this mutant protein could inhibit cell proliferation in a p53-dependent manner. As shown in Figure 4a , expression of wild-type B56g3 in the presence of p53 led to a dramatic decrease in cell proliferation, corresponding to a 45% reduction in cell number by 120 h. Interestingly, the F395C mutant was unable to block cell proliferation to a similar extent, with only a 20% decrease in cell number. The reduced inhibition of cell proliferation observed in the presence of the F395C mutant can be attributed to its p53independent function, as expression of the mutant in an isogenic p53 null background (HCT116 P53À/À) led to a decrease that showed no significant difference from that of wild-type B56g3 (P ¼ 0.08) (Figure 4a : Supplementary Figure S2 ). To provide further data correlating p53 interaction with p53-dependent functions of B56g3, we expressed the noninteracting QC mutant, as well as the interacting Q392G, C398L and QQ mutants in the same assay. The noninteracting QC mutant showed results similar to those of the F395C mutant, whereas those mutants that retained p53 interaction also retained similar p53-dependent functions comparable to wildtype B56g3 (Figure 4a ). As a control, lysates of the cell proliferation experiment were analyzed. As expected, increase in p21 protein levels occurred in the case of wild-type B56g3 but not F395C overexpression in HCT116 p53 þ / þ and HCT116 p53À/À cells, which correlated with the p53-dependent inhibition of cell proliferation (Figure 4a ).
To provide evidence that p53 Thr55 phosphorylation status contributes to the p53-dependent tumor-suppressive function of B56g, similar cell proliferation experiments were conducted in H1299 cells that lack functional wild-type p53. These cells were transfected with either wild-type p53 or a Thr55 to Asp mutant (T55D) that cannot be dephosphorylated at Thr55. As shown in Figure 4b , expression of wild-type B56g3, along with wild-type p53, led to a significant inhibition of cell proliferation, corresponding to a 50% decrease in cell number at 120 h. Expression of F395C mutant B56g3, however, led to only a small inhibition of cell proliferation, corresponding to approximately a 10% decrease in cell number. This small inhibition can be attributed to the Thr55 dephosphorylation-independent function, as a similar inhibition was observed in the presence of T55D mutant p53. Similarly, expression of the noninteracting QC mutant also led to a small inhibition of cell proliferation, supporting the notion that p53 interaction and Thr55 dephosphorylation are required for the p53-dependent tumor-suppressive function of B56g3 (Figure 4b ). Statistical analysis of the data is shown in Supplementary Figure S2 . Cell lysates from the experiment were subjected to western blot to assess p21 protein levels (Figure 4b) . The correlation between p21 induction and decrease in cell proliferation was again documented in the presence of wild-type p53 and B56g3. The lack of p21 induction in the presence of the F395C mutant B56g3 provides further evidence that this protein has lost its Thr55 dephosphorylation-dependent tumor-suppressive function. Taken together, our findings show for the first time that a cancer-derived mutant of B56g3 lacks the physiologically significant p53-dependent tumor-suppressive function, providing evidence for the importance of this pathway in protecting cells from a cancerous phenotype.
Discussion
In this study, we describe a novel molecular mechanism behind a cancer-derived loss of function mutation in the PP2A B56g regulatory subunit gene. This mutation was previously described in a lung tumor sample, although the functional significance of this mutation in tumorigenesis was not previously characterized. The missense mutation changes a phenylalanine residue at amino acid 395 to a cysteine within a region we mapped as being required for B56g-PP2A-p53 interaction. According to recent crystal structure data, this region maps to an area of high structural variability positioned in such a manner as to allow docking of the PP2A core with the substrate (Cho and Xu, 2006; Xu et al., 2006) . This provides further support to the notion that this region directly bridges the p53-PP2A interaction. In terms of tumorigenic function, we showed that the mutant protein has lost its ability to mediate the p53-dependent tumor-suppressive function of PP2A. Specifically, we showed that F395C is no longer able to interact with p53 or inhibit cultured cancer cell proliferation or growth on soft agar in a p53-dependent manner. Unfortunately, we are unable to assess p53 status in this identified cancer sample. However, recent data suggest that as many as 61% of lung tumors have wild-type p53 (Petitjean et al., 2007) , suggesting the importance of the B56g3-p53 interaction in regulating wild-type p53 tumor suppression function.
Although the F395C mutant lacks p53 interaction, it maintains its ability to interact with the PP2A core similar to wild-type protein (Figure 2a ). As such, we were able to show a competitive effect of F395C expression affecting the activity of the endogenous protein. It seems that even a single copy of this mutation may affect the function of the wild-type protein, because when levels of F395C expression are comparable to endogenous levels, there is a decrease in p53 Thr55 dephosphorylation after DNA damage (Figure 2d ). The mechanism for this interference seems to be the competition between the mutant and wild-type proteins for some other molecules required for function, as increasing the amount of expressed F395C protein enhances the effect. The molecule being titrated out may be the PP2A core complex, as both F395C and wild-type B56g can bind the PP2A core to similar levels. In addition, it does not seem as though the B56g protein can dimerize because HA-B56g3 was unable to interact with endogenous protein (Supplementary Figure S1) . These findings suggest that the mechanism for F395C interference with wild-type function is not dominant negative in the classical sense but is more because of competitive binding to other molecules.
Our investigation of the functional consequences of a previously described cancer-derived mutation in the B56g gene provides additional evidence of the importance of B56g in tumor suppression. Although the mutation was identified in a lung tumor sample complementary DNA library, the mutation was not present in the B56g gene sequence of normal lung tissue libraries present in the NIH database, suggesting that this mutation may have contributed to the phenotype of the tumor sample. In addition, as the mutation was not present in the NCBI single-nucleotide polymorphism database, it is not likely to be a polymorphism.
Although there was only one mutation found on the NIH database directly within the mapped p53 interaction domain, several mutations have been identified immediately outside this region that could potentially disrupt the p53-B56g interaction. We thus tested one of the mutants, A383G, which is immediately adjacent to the mapped p53 interaction domain (aa391-401; Suzuki et al., 2004; Supplementary Figure S3A ). Our results suggest that A383G also specifically lost its ability to interact with p53 ( Supplementary Figure S3B ). Furthermore, we showed that A383G is unable to promote p53 Thr55 dephosphorylation (Supplementary Figure S3C ) and the p53-dependent tumor-suppressive function of PP2A (Supplementary Figure S3D) . This finding supports our conclusion that interaction with p53 has an important role in PP2A-mediated activation of p53 and prevention of tumor progression. Perhaps it is worthwhile to mention that additional mutations have been detected in the B56g gene. For example, mutations that disrupt binding to the A and C subunits would potentially disrupt both the p53-dependent and -independent tumor-suppressive functions of this protein and may therefore be more common. Furthermore, the previously described mutations in the A subunit genes that contribute to tumorigenesis may function to disrupt the same pathway as this B56g mutation, thereby making B56g mutations in these cancer types less likely. Nevertheless, our study provides compelling biochemical data suggesting the importance of the F395C mutation and potentially other mutants in that expression of the mutant proteins no longer promotes PP2A-dependent activation of the tumor-suppressor protein p53 and actually disrupts the normal p53 response to DNA damage stress.
Although the cancer-derived F395C mutant protein no longer promotes a p53-dependent tumorsuppressive function, it still shows a less dramatic p53-independent function that has been previously described (Li et al., 2007) . Interestingly, this mutant protein is able to distinguish between these two and therefore provides compelling evidence as to the ability of the B subunits of PP2A to direct the holoenzyme to specific substrate targets and the potential for the presence of multiple substrate-binding domains within a single B subunit. Clearly, this subunit must promote PP2A-mediated dephosphorylation of other target proteins inside the cell that mediate this p53-independent function. Further study may provide insight into these protein targets and their role in PP2A-dependent tumor suppression, as well as into the domain of B56g responsible for mediating interaction with the PP2A substrate. Overall, although the regulation of PP2A functions is complex, our study adds significant support to the role of B56g-PP2A in tumor suppression, specifically through activation of the tumor-suppressor protein, p53.
Materials and methods
Identification of cancer-derived mutation
The AceView program, developed at NCBI, provides a strictly complementary DNA-supported view of the human transcriptome and genes by summarizing all quality-filtered human complementary DNA data from GenBank, dbEST and the RefSeq. Using this program, we looked for B56g mutations present within our identified p53 interaction domain for which the annotated sequencing data were taken from tumors, tumor samples and cancer cell lines. Our specific mutant was identified from a lung tumor sample and the corresponding gene accession number is BE829999.
Cell culture and plasmids U2OS, HCT116 or H1299 cells were cultured in McCoy's 5A, Dulbecco's modified Eagle's medium or RPMI 1640 medium supplemented with 10% fetal calf serum. The B56g3 deletion mutants, DN17, DN156, DC347, DC376 and DC401, were generated by PCR. The B56g3 point mutants, Q392G, C398L, Q392G/C398L, QQ400/401SS, F395C, were generated using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). All plasmids were verified by sequencing.
Western blot and immunoprecipitation
Whole-cell extract was prepared by lysing cells in a buffer containing 50 mM Tris-HCl (pH 8.0), 120 mM NaCl, 0.5% NP-40, 1 mM dithiothreitol, 2 mg/ml aprotinin and 2 mg/ml leupeptin. Cell lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by immunoblotting analysis with anti-p53 (DO1, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-p21 (C-19, Santa Cruz Biotechnology), anti-PP2A A subunit (Upstate, Lake Placid, NY, USA), anti-PP2A C subunit (1D6, Upstate), anti-PP2A B56g3 (against full-length B56g3), anti-ERK (Santa Cruz Biotechnology), anti-cyclin G (Santa Cruz Biotechnology), anti-SGOL1 (ABNOVA, Walnut, CA, USA), or antivinculin (VIN-11-5, Sigma, St Louis, MO, USA) antibodies. For Thr55 dephosphorylation, the cell lysate was immunoprecipitated with phospho-specific antibody for Thr55 (Ab202) and immunoblotted with anti-p53 antibody (Li et al., 2007) . For glutathione S-transferase pull-down experiments, glutathione S-transferase fusion proteins were expressed in BL21 bacteria and purified using glutathione sepharose beads. U2OS cell lysate or 35 S-labeled p53 was then incubated with the glutathione S-transferase protein. Precipitated proteins were then analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by immunoblotting or autoradiography. Peptide competition experiments were conducted by addition of different peptides to the reactions at 100-to 1000fold molar excess. For interaction of endogenous p53 with the transfected B56 proteins, U2OS cells were transfected with various B56 plasmids using FuGene (Roche, Nutley, NJ, USA) and lysed 28 h after transfection. Immunoprecipitation was performed using either anti-p53 polyclonal antibody (FL393, Santa Cruz Biotechnology) or anti-HA 12CA5 monoclonal antibody. The amounts of coprecipitated proteins were determined by immunoblotting.
Cell proliferation and anchorage-independent growth assays
To generate proliferation curves for HCT116 cells, cells were transfected with wild type, QC, F395C, Q392G, C398L or QQ mutant B56g3, or with a control cytomegalovirus empty vector, using Fugene, seeded in triplicate and counted at 0, 24, 48, 72, 96 and 120 h after seeding. To generate proliferation curves for H1299 cells, cells were co-transfected with wild type, QC, F395C, Q392G, C398L or QQ mutant B56g3, or with a control cytomegalovirus empty vector, along with either wild-type p53 or T55D mutant p53, using Fugene, seeded in triplicate and counted at 0, 24, 48, 72, 96 and 120 h after seeding. For anchorage-independent growth assays of HCT116 cells, cells were transfected with wild type, Q392G, C398L, QC, QQ or F395C mutant B56g3, or with a control cytomegalovirus empty vector, seeded in triplicate in 0.35% Noble Agar (Fisher) and counted 4 weeks after seeding.
